Trials / Recruiting
RecruitingNCT04617522
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
A Phase 1, Open-Label, Dose-Escalation Study to Determine an Appropriate Starting Dose of Sacituzumab Govitecan in Subjects With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goals of this clinical study are to learn more about the safety and dosing of the study drug, sacituzumab govitecan-hziy, in participants with solid tumors and moderate liver problems.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sacituzumab Govitecan-hziy | Administered intravenously |
Timeline
- Start date
- 2021-04-06
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2020-11-05
- Last updated
- 2026-02-11
Locations
13 sites across 3 countries: United States, France, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04617522. Inclusion in this directory is not an endorsement.